188 related articles for article (PubMed ID: 10829072)
21. Identification of potential binding pocket on viral oncoprotein HPV16 E6: a promising anti-cancer target for small molecule drug discovery.
Kolluru S; Momoh R; Lin L; Mallareddy JR; Krstenansky JL
BMC Mol Cell Biol; 2019 Aug; 20(1):30. PubMed ID: 31387520
[TBL] [Abstract][Full Text] [Related]
22. Adenovirus-mediated transfer of human papillomavirus 16 E6/E7 antisense RNA and induction of apoptosis in cervical cancer.
Hamada K; Shirakawa T; Gotoh A; Roth JA; Follen M
Gynecol Oncol; 2006 Dec; 103(3):820-30. PubMed ID: 16908054
[TBL] [Abstract][Full Text] [Related]
23. HPV16 E6 oncoprotein increases cell adhesion in human keratinocytes.
Epshtein A; Jackman A; Gonen P; Sherman L
Arch Virol; 2009; 154(1):55-63. PubMed ID: 19066713
[TBL] [Abstract][Full Text] [Related]
24. The E6AP binding pocket of the HPV16 E6 oncoprotein provides a docking site for a small inhibitory peptide unrelated to E6AP, indicating druggability of E6.
Zanier K; Stutz C; Kintscher S; Reinz E; Sehr P; Bulkescher J; Hoppe-Seyler K; Travé G; Hoppe-Seyler F
PLoS One; 2014; 9(11):e112514. PubMed ID: 25383876
[TBL] [Abstract][Full Text] [Related]
25. Structural and functional analysis of E6 oncoprotein: insights in the molecular pathways of human papillomavirus-mediated pathogenesis.
Nominé Y; Masson M; Charbonnier S; Zanier K; Ristriani T; Deryckère F; Sibler AP; Desplancq D; Atkinson RA; Weiss E; Orfanoudakis G; Kieffer B; Travé G
Mol Cell; 2006 Mar; 21(5):665-78. PubMed ID: 16507364
[TBL] [Abstract][Full Text] [Related]
26. The domain of p53 required for binding HPV 16 E6 is separable from the degradation domain.
Mansur CP; Marcus B; Dalal S; Androphy EJ
Oncogene; 1995 Feb; 10(3):457-65. PubMed ID: 7845670
[TBL] [Abstract][Full Text] [Related]
27. Domain substructure of HPV E6 oncoprotein: biophysical characterization of the E6 C-terminal DNA-binding domain.
Nominé Y; Charbonnier S; Ristriani T; Stier G; Masson M; Cavusoglu N; Van Dorsselaer A; Weiss E; Kieffer B; Travé G
Biochemistry; 2003 May; 42(17):4909-17. PubMed ID: 12718532
[TBL] [Abstract][Full Text] [Related]
28. Human papillomavirus type 16 E6 and E7 oncoproteins upregulate c-IAP2 gene expression and confer resistance to apoptosis.
Yuan H; Fu F; Zhuo J; Wang W; Nishitani J; An DS; Chen IS; Liu X
Oncogene; 2005 Jul; 24(32):5069-78. PubMed ID: 15856013
[TBL] [Abstract][Full Text] [Related]
29. Mechanism of HPV E6 proteins in cellular transformation.
Huibregtse JM; Beaudenon SL
Semin Cancer Biol; 1996 Dec; 7(6):317-26. PubMed ID: 9284524
[TBL] [Abstract][Full Text] [Related]
30. Chemotherapy compounds in cervical cancer cells primed by reconstitution of p53 function after short interfering RNA-mediated degradation of human papillomavirus 18 E6 mRNA: opposite effect of siRNA in combination with different drugs.
Koivusalo R; Krausz E; Helenius H; Hietanen S
Mol Pharmacol; 2005 Aug; 68(2):372-82. PubMed ID: 15908516
[TBL] [Abstract][Full Text] [Related]
31. HPV E6 oncoprotein as a potential therapeutic target in HPV related cancers.
Manzo-Merino J; Thomas M; Fuentes-Gonzalez AM; Lizano M; Banks L
Expert Opin Ther Targets; 2013 Nov; 17(11):1357-68. PubMed ID: 24094136
[TBL] [Abstract][Full Text] [Related]
32. Protein intrinsic disorder and human papillomaviruses: increased amount of disorder in E6 and E7 oncoproteins from high risk HPVs.
Uversky VN; Roman A; Oldfield CJ; Dunker AK
J Proteome Res; 2006 Aug; 5(8):1829-42. PubMed ID: 16889404
[TBL] [Abstract][Full Text] [Related]
33. Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner.
López-Ocejo O; Viloria-Petit A; Bequet-Romero M; Mukhopadhyay D; Rak J; Kerbel RS
Oncogene; 2000 Sep; 19(40):4611-20. PubMed ID: 11030150
[TBL] [Abstract][Full Text] [Related]
34. RNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatin.
Putral LN; Bywater MJ; Gu W; Saunders NA; Gabrielli BG; Leggatt GR; McMillan NA
Mol Pharmacol; 2005 Nov; 68(5):1311-9. PubMed ID: 16120770
[TBL] [Abstract][Full Text] [Related]
35. The presence of human papillomavirus-16/-18 E6, p53, and Bcl-2 protein in cervicovaginal smears from patients with invasive cervical cancer.
Pillai MR; Halabi S; McKalip A; Jayaprakash PG; Rajalekshmi TN; Nair MK; Herman B
Cancer Epidemiol Biomarkers Prev; 1996 May; 5(5):329-35. PubMed ID: 9162297
[TBL] [Abstract][Full Text] [Related]
36. HPV16 E6 oncoprotein stimulates the transforming growth factor-beta 1 promoter in fibroblasts through a specific GC-rich sequence.
Dey A; Atcha IA; Bagchi S
Virology; 1997 Feb; 228(2):190-9. PubMed ID: 9123825
[TBL] [Abstract][Full Text] [Related]
37. Specific recognition of four-way DNA junctions by the C-terminal zinc-binding domain of HPV oncoprotein E6.
Ristriani T; Nominé Y; Masson M; Weiss E; Travé G
J Mol Biol; 2001 Jan; 305(4):729-39. PubMed ID: 11162088
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical co-expression of human papillomavirus type 16/18 transforming (E6) oncoprotein and p53 tumour suppressor gene proteins in oesophageal cancer.
Agarwal SK; Chatterji A; Bhambhani S; Sharma BK
Indian J Exp Biol; 1998 Jun; 36(6):559-63. PubMed ID: 9731468
[TBL] [Abstract][Full Text] [Related]
39. siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells.
Butz K; Ristriani T; Hengstermann A; Denk C; Scheffner M; Hoppe-Seyler F
Oncogene; 2003 Sep; 22(38):5938-45. PubMed ID: 12955072
[TBL] [Abstract][Full Text] [Related]
40. Advances in the development of ribozymes and antisense oligodeoxynucleotides as antiviral agents for human papillomaviruses.
Alvarez-Salas LM; Benítez-Hess ML; DiPaolo JA
Antivir Ther; 2003 Aug; 8(4):265-78. PubMed ID: 14518695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
